Insiders · OGN

Robert Essner

Director at Organon & Co. (OGN)

Robert Essner has filed 7 insider reports with the SEC since June 2021, as director at Organon & Co. (OGN) and director at Amicus Therapeutics, Inc. (FOLD). The latest filing, on June 15, 2026, reports grant or award at Organon & Co. (OGN).

Filings
7
Companies
2
Bought on market
None
Sold on market
None

Companies where Robert Essner is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Organon & Co. logo
OGN
Organon & Co.
Director$13.92Jun 15, 2026
Amicus Therapeutics, Inc. logo
FOLD
Amicus Therapeutics, Inc.
Director31,115Jun 14, 2021

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Robert Essner with

Other insiders at the same companies

Questions about Robert Essner

What is Robert Essner's role at Organon & Co.?
Robert Essner reports to the SEC as director at Organon & Co. (OGN), according to the latest filing on June 15, 2026. Robert Essner has also filed as director at Amicus Therapeutics, Inc. (FOLD).
How many shares does Robert Essner own?
After the latest filing that states it, Robert Essner directly owned 31,115 shares of Amicus Therapeutics, Inc. (FOLD). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Robert Essner bought or sold stock recently?
No open-market purchases or sales by Robert Essner are on file. The filings report grant or award.
How do I get alerts when Robert Essner files?
Follow Robert Essner on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Robert Essner (SEC CIK 0001187297). Totals count each trade once, skipping amendments whose original is on file, from Jun 9, 2021 on. View on SEC EDGAR